GlaxoSmithKline plc (LSE/NYSE:GSK) and Vir Biotechnology (Nasdaq:VIR) have announced that FDA has concluded that the investigational monoclonal antibody sotrovimab is unlikely to be effective against the omicron BA.2 subvariant, which will soon dominate the U.S.
FDA has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab and its website to exclude the antibody in certain areas.
GSK and Vir were initially optimistic about the antibody’s ability to target the mutations in the spike protein of the original omicron SARS-CoV-2 variant.
Vir shares dropped 13.56% to $21.81. GSK shares were mostly flat, falling 0.046% to $43.28.
The market for SARS-CoV-2 antibodies has been competitive, but emerging variants have limited use of the therapies.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended marketing authorization for AstraZeneca’s (LON:AZN) Evusheld to protect against COVID-19 in adults and some adolescents.
Filed Under: Infectious Disease